Potential for Residual Cardiovascular Risk Reduction: Eligibility for Icosapent Ethyl in the VERTIS CV Population with Type 2 Diabetes and Atherosclerotic Cardiovascular Disease.
Joseph M KimDeepak L BhattSamuel Dagogo-JackDavid Z I CherneyFrancesco CosentinoDarren K McGuireRichard E PratleyChih-Chin LiuNilo B CaterRobert FrederichJames P MancusoChristopher P CannonPublished in: Diabetes, obesity & metabolism (2023)